Binding Assay:Article Title: Neutralizing antibodies to human endothelin
Article Snippet: The present invention includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising a heavy chain complementarity determining region (CDR) 1, a heavy chain variable region CDR2, a heavy chain variable region CDR3, a light chain variable region CDR1, a light chain variable region CDR2, and a light chain variable region CDR3 of the monoclonal antibody produced by the hybridoma cell line Nab #7 3G 9A4 deposited under ATCC[[®]] Patent Deposit Designation PTA-125818. .. The present invention includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising a heavy chain complementarity determining region (CDR) 1, a heavy chain variable region CDR2, a heavy chain variable region CDR3, a light chain variable region CDR1, a light chain variable region CDR2, and a light chain variable region CDR3 of the monoclonal antibody produced by the hybridoma cell line Nab #1 5D 1087 deposited under ATCC[[®]] Patent Deposit Designation PTA-125819. .. The present invention includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising the heavy chain variable region (VH) and light chain variable region (VL) of the monoclonal antibody produced by the hybridoma cell line Nab #15 7D 489 deposited under ATCC[[®]] Patent Deposit Designation PTA-125817.
Article Title: Neutralizing antibodies to human endothelin
Article Snippet: One embodiment includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising a heavy chain complementarity determining region (CDR) 1, a heavy chain variable region CDR2, a heavy chain variable region CDR3, a light chain variable region CDR1, a light chain variable region CDR2, and a light chain variable region CDR3 of the monoclonal antibody produced by the hybridoma cell line Nab #1 5D 1087 deposited under ATCC[[®]] Patent Deposit Designation PTA-125819. .. One embodiment includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising the heavy chain variable region (VH) and light chain variable region (VL) of the monoclonal antibody produced by the hybridoma cell line Nab #15 7D 489 deposited under ATCC[[®]] Patent Deposit Designation PTA-125817. .. One embodiment includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising the heavy chain variable region (VH) and light chain variable region (VL) of the monoclonal antibody produced by the hybridoma cell line Nab #7 3G 9A4 deposited under ATCC[[®]] Patent Deposit Designation PTA-125818.
Article Title: Neutralizing antibodies to human endothelin
Article Snippet: One embodiment includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising a heavy chain complementarity determining region (CDR) 1, a heavy chain variable region CDR2, a heavy chain variable region CDR3, a light chain variable region CDR1, a light chain variable region CDR2, and a light chain variable region CDR3 of the monoclonal antibody produced by the hybridoma cell line Nab #7 3G 9A4 deposited under ATCC[[®]] Patent Deposit Designation PTA-125818. .. One embodiment includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising a heavy chain complementarity determining region (CDR) 1, a heavy chain variable region CDR2, a heavy chain variable region CDR3, a light chain variable region CDR1, a light chain variable region CDR2, and a light chain variable region CDR3 of the monoclonal antibody produced by the hybridoma cell line Nab #1 5D 1087 deposited under ATCC[[®]] Patent Deposit Designation PTA-125819. .. One embodiment includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising the heavy chain variable region (VH) and light chain variable region (VL) of the monoclonal antibody produced by the hybridoma cell line Nab #15 7D 489 deposited under ATCC[[®]] Patent Deposit Designation PTA-125817.
Article Title: Neutralizing antibodies to human endothelin
Article Snippet: One embodiment includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising the heavy chain variable region (VH) and light chain variable region (VL) of the monoclonal antibody produced by the hybridoma cell line Nab #15 7D 489 deposited under ATCC[[®]] Patent Deposit Designation PTA-125817. .. One embodiment includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising the heavy chain variable region (VH) and light chain variable region (VL) of the monoclonal antibody produced by the hybridoma cell line Nab #7 3G 9A4 deposited under ATCC[[®]] Patent Deposit Designation PTA-125818. .. One embodiment includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising the heavy chain variable region (VH) and light chain variable region (VL) of the monoclonal antibody produced by the hybridoma cell line Nab #1 5D 1087 deposited under ATCC[[®]] Patent Deposit Designation PTA-125819.
Article Title: Neutralizing antibodies to human endothelin
Article Snippet: The present invention includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising the heavy chain variable region (VH) and light chain variable region (VL) of the monoclonal antibody produced by the hybridoma cell line Nab #15 7D 489 deposited under ATCC[[®]] Patent Deposit Designation PTA-125817. .. The present invention includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising the heavy chain variable region (VH) and light chain variable region (VL) of the monoclonal antibody produced by the hybridoma cell line Nab #7 3G 9A4 deposited under ATCC[[®]] Patent Deposit Designation PTA-125818. .. The present invention includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising the heavy chain variable region (VH) and light chain variable region (VL) of the monoclonal antibody produced by the hybridoma cell line Nab #1 5D 1087 deposited under ATCC[[®]] Patent Deposit Designation PTA-125819.
Article Title: Neutralizing antibodies to human endothelin
Article Snippet: The present invention includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising a heavy chain complementarity determining region (CDR) 1, a heavy chain variable region CDR2, a heavy chain variable region CDR3, a light chain variable region CDR1, a light chain variable region CDR2, and a light chain variable region CDR3 of the monoclonal antibody produced by the hybridoma cell line Nab #1 5D 1087 deposited under ATCC[[®]] Patent Deposit Designation PTA-125819. .. The present invention includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising the heavy chain variable region (VH) and light chain variable region (VL) of the monoclonal antibody produced by the hybridoma cell line Nab #15 7D 489 deposited under ATCC[[®]] Patent Deposit Designation PTA-125817. .. The present invention includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising the heavy chain variable region (VH) and light chain variable region (VL) of the monoclonal antibody produced by the hybridoma cell line Nab #7 3G 9A4 deposited under ATCC[[®]] Patent Deposit Designation PTA-125818.
Article Title: Neutralizing antibodies to human endothelin
Article Snippet: One embodiment includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising the heavy chain variable region (VH) and light chain variable region (VL) of the monoclonal antibody produced by the hybridoma cell line Nab #7 3G 9A4 deposited under ATCC[[®]] Patent Deposit Designation PTA-125818. .. One embodiment includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising the heavy chain variable region (VH) and light chain variable region (VL) of the monoclonal antibody produced by the hybridoma cell line Nab #1 5D 1087 deposited under ATCC[[®]] Patent Deposit Designation PTA-125819. .. One embodiment includes the monoclonal antibody produced by hybridoma cell line Nab #15 7D 489 deposited under ATCC[[®]] Patent Deposit Designation PTA-125817, or an antigen binding fragment thereof.
Produced:Article Title: Neutralizing antibodies to human endothelin
Article Snippet: The present invention includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising a heavy chain complementarity determining region (CDR) 1, a heavy chain variable region CDR2, a heavy chain variable region CDR3, a light chain variable region CDR1, a light chain variable region CDR2, and a light chain variable region CDR3 of the monoclonal antibody produced by the hybridoma cell line Nab #7 3G 9A4 deposited under ATCC[[®]] Patent Deposit Designation PTA-125818. .. The present invention includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising a heavy chain complementarity determining region (CDR) 1, a heavy chain variable region CDR2, a heavy chain variable region CDR3, a light chain variable region CDR1, a light chain variable region CDR2, and a light chain variable region CDR3 of the monoclonal antibody produced by the hybridoma cell line Nab #1 5D 1087 deposited under ATCC[[®]] Patent Deposit Designation PTA-125819. .. The present invention includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising the heavy chain variable region (VH) and light chain variable region (VL) of the monoclonal antibody produced by the hybridoma cell line Nab #15 7D 489 deposited under ATCC[[®]] Patent Deposit Designation PTA-125817.
Article Title: Neutralizing antibodies to human endothelin
Article Snippet: One embodiment includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising a heavy chain complementarity determining region (CDR) 1, a heavy chain variable region CDR2, a heavy chain variable region CDR3, a light chain variable region CDR1, a light chain variable region CDR2, and a light chain variable region CDR3 of the monoclonal antibody produced by the hybridoma cell line Nab #1 5D 1087 deposited under ATCC[[®]] Patent Deposit Designation PTA-125819. .. One embodiment includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising the heavy chain variable region (VH) and light chain variable region (VL) of the monoclonal antibody produced by the hybridoma cell line Nab #15 7D 489 deposited under ATCC[[®]] Patent Deposit Designation PTA-125817. .. One embodiment includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising the heavy chain variable region (VH) and light chain variable region (VL) of the monoclonal antibody produced by the hybridoma cell line Nab #7 3G 9A4 deposited under ATCC[[®]] Patent Deposit Designation PTA-125818.
Article Title: Neutralizing antibodies to human endothelin
Article Snippet: One embodiment includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising a heavy chain complementarity determining region (CDR) 1, a heavy chain variable region CDR2, a heavy chain variable region CDR3, a light chain variable region CDR1, a light chain variable region CDR2, and a light chain variable region CDR3 of the monoclonal antibody produced by the hybridoma cell line Nab #7 3G 9A4 deposited under ATCC[[®]] Patent Deposit Designation PTA-125818. .. One embodiment includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising a heavy chain complementarity determining region (CDR) 1, a heavy chain variable region CDR2, a heavy chain variable region CDR3, a light chain variable region CDR1, a light chain variable region CDR2, and a light chain variable region CDR3 of the monoclonal antibody produced by the hybridoma cell line Nab #1 5D 1087 deposited under ATCC[[®]] Patent Deposit Designation PTA-125819. .. One embodiment includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising the heavy chain variable region (VH) and light chain variable region (VL) of the monoclonal antibody produced by the hybridoma cell line Nab #15 7D 489 deposited under ATCC[[®]] Patent Deposit Designation PTA-125817.
Article Title: Neutralizing antibodies to human endothelin
Article Snippet: One embodiment includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising the heavy chain variable region (VH) and light chain variable region (VL) of the monoclonal antibody produced by the hybridoma cell line Nab #15 7D 489 deposited under ATCC[[®]] Patent Deposit Designation PTA-125817. .. One embodiment includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising the heavy chain variable region (VH) and light chain variable region (VL) of the monoclonal antibody produced by the hybridoma cell line Nab #7 3G 9A4 deposited under ATCC[[®]] Patent Deposit Designation PTA-125818. .. One embodiment includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising the heavy chain variable region (VH) and light chain variable region (VL) of the monoclonal antibody produced by the hybridoma cell line Nab #1 5D 1087 deposited under ATCC[[®]] Patent Deposit Designation PTA-125819.
Article Title: Neutralizing antibodies to human endothelin
Article Snippet: The present invention includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising the heavy chain variable region (VH) and light chain variable region (VL) of the monoclonal antibody produced by the hybridoma cell line Nab #15 7D 489 deposited under ATCC[[®]] Patent Deposit Designation PTA-125817. .. The present invention includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising the heavy chain variable region (VH) and light chain variable region (VL) of the monoclonal antibody produced by the hybridoma cell line Nab #7 3G 9A4 deposited under ATCC[[®]] Patent Deposit Designation PTA-125818. .. The present invention includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising the heavy chain variable region (VH) and light chain variable region (VL) of the monoclonal antibody produced by the hybridoma cell line Nab #1 5D 1087 deposited under ATCC[[®]] Patent Deposit Designation PTA-125819.
Article Title: Neutralizing antibodies to human endothelin
Article Snippet: The present invention includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising a heavy chain complementarity determining region (CDR) 1, a heavy chain variable region CDR2, a heavy chain variable region CDR3, a light chain variable region CDR1, a light chain variable region CDR2, and a light chain variable region CDR3 of the monoclonal antibody produced by the hybridoma cell line Nab #1 5D 1087 deposited under ATCC[[®]] Patent Deposit Designation PTA-125819. .. The present invention includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising the heavy chain variable region (VH) and light chain variable region (VL) of the monoclonal antibody produced by the hybridoma cell line Nab #15 7D 489 deposited under ATCC[[®]] Patent Deposit Designation PTA-125817. .. The present invention includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising the heavy chain variable region (VH) and light chain variable region (VL) of the monoclonal antibody produced by the hybridoma cell line Nab #7 3G 9A4 deposited under ATCC[[®]] Patent Deposit Designation PTA-125818.
Article Title: Neutralizing antibodies to human endothelin
Article Snippet: One embodiment includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising the heavy chain variable region (VH) and light chain variable region (VL) of the monoclonal antibody produced by the hybridoma cell line Nab #7 3G 9A4 deposited under ATCC[[®]] Patent Deposit Designation PTA-125818. .. One embodiment includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising the heavy chain variable region (VH) and light chain variable region (VL) of the monoclonal antibody produced by the hybridoma cell line Nab #1 5D 1087 deposited under ATCC[[®]] Patent Deposit Designation PTA-125819. .. One embodiment includes the monoclonal antibody produced by hybridoma cell line Nab #15 7D 489 deposited under ATCC[[®]] Patent Deposit Designation PTA-125817, or an antigen binding fragment thereof.
Expressing:Article Title: From byproduct to biotherapeutic: Comparative study of buffy coats and leukoreduction system chambers for NK cell-based immunotherapies
Article Snippet: K562 (ATCC CCL-243) were maintained in RPMI 1640 supplemented with 10% fetal bovine serum (Bio&Sell, Feucht/Nürnberg, Germany), 1% L-glutamine (Bio&Sell, Feucht/Nürnberg, Germany), and 1% penicillin-streptomycin (PAN Biotech, Aidenbach, Germany) under humidified conditions at 37°C and 5% CO 2 . .. Cell line authentication other than target antigen expression for MDA-MB-453 was not conducted in-house; however, all cell lines were obtained from ATCC (distributed by LGC Standards GmbH, Wesel, Germany), which provides comprehensive certificates of analysis verifying their identity and quality. ..
Multiple Displacement Amplification:Article Title: From byproduct to biotherapeutic: Comparative study of buffy coats and leukoreduction system chambers for NK cell-based immunotherapies
Article Snippet: K562 (ATCC CCL-243) were maintained in RPMI 1640 supplemented with 10% fetal bovine serum (Bio&Sell, Feucht/Nürnberg, Germany), 1% L-glutamine (Bio&Sell, Feucht/Nürnberg, Germany), and 1% penicillin-streptomycin (PAN Biotech, Aidenbach, Germany) under humidified conditions at 37°C and 5% CO 2 . .. Cell line authentication other than target antigen expression for MDA-MB-453 was not conducted in-house; however, all cell lines were obtained from ATCC (distributed by LGC Standards GmbH, Wesel, Germany), which provides comprehensive certificates of analysis verifying their identity and quality. ..
|